MARKET

VTVT

VTVT

Vtv Therapeutics
NASDAQ
19.69
-1.00
-4.83%
After Hours: 19.69 0 0.00% 16:10 11/13 EST
OPEN
20.81
PREV CLOSE
20.69
HIGH
20.81
LOW
19.04
VOLUME
17.40K
TURNOVER
--
52 WEEK HIGH
44.00
52 WEEK LOW
19.04
MARKET CAP
78.99M
P/E (TTM)
-21.6041
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at VTVT last week (1102-1106)?
Weekly Report · 4d ago
vTv Therapeutics GAAP EPS of -$0.94 beats by $0.15
Seeking Alpha · 11/05 22:50
Press Release: vTv Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Dow Jones · 11/05 21:01
Press Release: vTv Therapeutics Reports Third -2-
Dow Jones · 11/05 21:01
*vTv Therapeutics 3Q Loss/Shr 94c >VTVT
Dow Jones · 11/05 21:01
VTv Therapeutics: Q3 Earnings Snapshot
Barchart · 11/05 15:32
Weekly Report: what happened at VTVT last week (1026-1030)?
Weekly Report · 11/02 09:01
vTv Therapeutics Announces First Patient Randomized In Phase 2a Hybrid CATT1 Study Of Cadisegliatin In Type 1 Diabetes
Benzinga · 10/27 12:08
More
About VTVT
vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for metabolic and inflammatory diseases. Its product pipeline includes TTP399, TTP273, HPP737 and HPP593. The lead product candidate, cadisegliatin (TTP399), is an orally administered, small-molecule, liver-selective glucokinase activator (GKA) that is a potential adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D). HPP737 is an orally administered, non-central nervous system (non-CNS) penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases and offers the potential for an improved tolerability profile and efficacy over commercially available PDE4 inhibitors. TTP273 is an oral, small molecule, glucagon-like peptide 1 (GLP-1) receptor agonist being evaluated for the treatment of type 2 diabetes mellitus. Its product pipeline also includes Azeliragon and HPP3033.

Webull offers vTv Therapeutics Inc stock information, including NASDAQ: VTVT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VTVT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading VTVT stock methods without spending real money on the virtual paper trading platform.